Human Hepatitis B Immunoglobulin Bio Products Laboratory (Human Hepatitis B Immunoglobulin)

Human Hepatitis B Immunoglobulin is indicated for specific clinical situations where immediate hepatitis B virus (HBV) protection is needed.

• Post‑exposure prophylaxis (PEP) after known or suspected exposure to HBV.
• Prevention of HBV infection in newborns of HBsAg‑positive mothers when active vaccination is contraindicated.
• Prevention of HBV recurrence following orthotopic liver transplantation.
• Supplementation of active hepatitis B vaccination in patients with poor vaccine response.
• Use in individuals with chronic kidney disease undergoing dialysis who lack adequate anti‑HBs antibodies.

• Human Hepatitis B Immunoglobulin supplies exogenous anti‑HBsAg antibodies that bind to the hepatitis B surface antigen, neutralizing circulating virus particles and blocking their attachment to hepatocyte receptors. This passive immunization prevents viral entry into liver cells, facilitates opsonization and clearance by the reticuloendothelial system, and provides immediate short‑term protection while the host’s active immune response develops.

Adverse reactions to Human Hepatitis B Immunoglobulin are generally related to the injection and immune response.

Common

• Injection site pain, redness, or swelling.
• Mild fever or chills.
• Headache or fatigue.
• Nausea or transient gastrointestinal discomfort.
• Transient rash or urticaria.

Serious

• Anaphylactic or severe allergic reaction.
• Serum sickness‑like illness.
• Acute hemolysis.
• Thrombocytopenia or bleeding disorders.
• Acute renal failure or interstitial nephritis.
• Severe hypotension or shock.

Human Hepatitis B Immunoglobulin should be used with careful clinical assessment.

• Do not administer to patients with known hypersensitivity to human immunoglobulins or any excipients.
• Pregnancy and lactation status are not well established; use only if potential benefit justifies the risk.
• Assess HBV serology and immune status before administration.
• Monitor for signs of allergic reaction during and after injection.
• Use cautiously in individuals with IgA deficiency or severe immunodeficiency.
• Coordinate timing with active hepatitis B vaccination to avoid interference.
• Ensure proper intramuscular technique to reduce local tissue injury.

Human Hepatitis B Immunoglobulin may interact with other therapies.

Avoid

• Concurrent administration of other blood products containing immunoglobulins, which may increase the risk of hypersensitivity.
• Live vaccines given within 4 weeks of immunoglobulin, as passive antibodies can diminish vaccine efficacy.

Use with caution

• Immunosuppressive agents (e.g., corticosteroids, azathioprine) that may alter immune response.
• Anticoagulants or antiplatelet drugs, due to potential for increased bleeding at the injection site.
• Other hepatitis B vaccines or immune globulins, requiring spacing to prevent interference.
• Monoclonal antibodies targeting B‑cells (e.g., rituximab) that may affect antibody clearance.